List view / Grid view
Sanofi announced that the U.S. Food and Drug Administration has…
8 July 2014 | By Sanofi
Sanofi announced that the U.S. Food and Drug Administration has accepted for review the company’s New Drug Application for Toujeo®...
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo®…
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...
EDITION II trial demonstrates similar blood sugar control with fewer…
3 December 2013 | By Sanofi
EDITION II trial demonstrates similar blood sugar control with fewer night-time low blood sugar events for U300 compared with Lantus®...
Japan’s MHLW has approved the manufacturing and distribution of Lyxumia®...
28 June 2013 | By Sanofi
Japan’s MHLW has approved the manufacturing and distribution of Lyxumia®...
Topline results of EDITION II consistent with EDITION I findings...
22 June 2013 | By Sanofi
Topline results of EDITION II consistent with EDITION I findings...
Sanofi announced that the U.S. FDA has accepted for review…
19 February 2013 | By Sanofi
Sanofi announced that the U.S. FDA has accepted for review a New Drug Application for lixisenatide...
Sanofi portfolio expands to offer first once-a-day prandial GLP-1 receptor…
4 February 2013 | By Sanofi
Sanofi portfolio expands to offer first once-a-day prandial GLP-1 receptor agonist...
“The CHMP positive opinion for Lyxumia marks an important milestone..."
16 November 2012 | By Sanofi
“The CHMP positive opinion for Lyxumia marks an important milestone..."
Sanofi announced the launch by Sanofi India Limited of AllStar™...
9 October 2012 | By Sanofi
Sanofi announced the launch by Sanofi India Limited of AllStar™...
Data from phase III GetGoal Duo 1 study...
6 December 2011 | By Sanofi
Data from phase III GetGoal Duo 1 study...
